Breo Ellipta is filed at FDA for treatment of Asthma- GSK + Theravance
GlaxoSmithKline plc and Theravance, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA for a fixed dose combination of the inhaled corticosteroid, fluticasone furoate and the long-acting beta2 agonist, vilanterol (FF/VI) as a once-daily treatment for Asthma in patients aged 12 years and older, with the brand name of Breo Ellipta.
The sNDA is seeking approval for two dose regimens, 100/25mcg and 200/25mcg, administered once daily using the Ellipta dry powder inhaler.The filing is based upon data generated from the comprehensive clinical development programme for FF/VI in Asthma. The clinical development programme comprised 48 clinical pharmacology studies in 1,328 subjects and 23 clinical studies in 12,051 patients with Asthma, including the Phase III efficacy and safety study of FF/VI reported in December 2013.
530 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.